Crinetics Pharmaceuticals (CRNX) Current Assets (2017 - 2026)

Crinetics Pharmaceuticals has reported Current Assets for 10 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 2.43% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 2.43% YoY), and the FY2025 full-year result was $1.0 billion, down 23.78% from the prior year.
• Current Assets for Q1 2026 stood at $1.3 billion, up from $1.0 billion in the prior quarter.
• The five-year high for Current Assets was $1.4 billion in Q4 2024, with the low at $284.8 million in Q2 2023.
• Average Current Assets over 5 years is $779.6 million, with a median of $874.8 million recorded in 2024.
• Year-over-year, Current Assets slumped 31.58% in 2023 and soared 207.14% in 2024.
• Tracing CRNX's Current Assets over 5 years: stood at $345.2 million in 2022, then jumped by 66.33% to $574.2 million in 2023, then jumped by 139.55% to $1.4 billion in 2024, then fell by 23.78% to $1.0 billion in 2025, then rose by 26.14% to $1.3 billion in 2026.
• The last three Current Assets figures came in at $1.3 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison